THUNDER BAY, Ontario--(BUSINESS WIRE)--Mitomics, world leader in research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced that its shareholders have voted to change the company name from Genesis Genomics Inc. to Mitomics Inc., effective immediately. The change is being implemented as the company begins commercialization of the Prostate Core Mitomic Test™ based on its Mitomic Technology™ platform in the United States this year.
